Somatostatin is a potent inhibitory hormone, it's synthetic analogue is more potent and has a prolonged action. It has a wide range of actions in the gastrointestinal system; among which is an anticholeritic action on bile secretion. 
The use of Sandostatin in the management of a case of complicated biliary fistula is reported; it controlled the fistula reducing its daily output from 200 ml to less than 5 A small butterfly needle, was inserted into the CBD to perform cholangiography, which showed 3 filling defects. The stones were removed through a choledochotomy and a T-tube was inserted. The gallbladder was not removed and no biliary enteric anastomosis performed. Postoperatively, the histology report of the excised cysts was that it was typical of Caroli's disease. The T-tube cholangiography showed no evidence of stones in the CBD and contrast was seen in the duodenum. When, the T-tube was removed the tract persisted as a biliary fistula which was resistant to any attempt to close it including cholecystojujenostomy; done as a 2nd operation, the output was 150-200 mls. per day and that was for almost 12 months. During the late course of his illness, the child developed generalized psoriatic skin-lesions which was then diagnosed as due to histocystosis-X. Bone marrow examination confirmed that the disease had spread to bone marrow. Treatment for histocystosis-X by cytotoxic therapy was given but it had no effect on the fistula. It's effect on bile secretion has been studied in several experimental models, it reduces bile secretion in rats (1) and has an anticholeretic effect in dogs (z).
In man, Somatostatin reduces the bile secretion by 30-40%, it acts on the bile acid-dependent canalicular bile secretion and also on the bile acid-independent ductular secretion (3) SMS-201-995 almost abolishes the cholecystokinin release and gallbladder contraction (4) .
Inspite of such evidences in animal and normal humans, there is only one case report of using -.. (5) .
Sandostatin in biliary fistut
This case is the second and for thefirst time, it is used for a long time in a paediatric patient with biliary fistula.
Although it did not heal the fistula; there are advantages for using Sandostatin; the metabolic and skin complications of high output biliary fistula are avoided, the patient can eat normally and there is no need for prolonged TPN, there is no need for a collection bag or PTC to collect the bile as the amount is minimal and daily dressing is sufficient; and because the drug is given subcutaneously hospitalization is also not needed. The non-healing may be due to infiltration of the tract by histocystosis-X or due to inadequate distal drainage. The biliary enteric anastomosis-choledochoduodenostomy or choledochojujenustomy-was not performed in the 1st operation because of fear of causing recurrent cholangitis <6) in a young child, of the second attempt, it was very difficult to reach the common bile duct so cholecystojujenostomy was performed but it also failed to control the fistula.
At the beginning of the treatment with Sandostatin, the patient had abdominal pain which is controlled by "Buscopan" suppositories given prior to the Sandostatin dose. This was needed only in the first 2 weeks, no side effect were seen after prolonged use of this a high dose, not even gallstones.
The use of Sandostatin is to be recommended in cases of biliary fistula and there is no need to deprive the patient of oral intake, although healing has not been accomplished in this case, control is adequate and healing may be accomplished in other cases.
